Genzyme Oncology
Genzyme Oncology
500 Kendall St.
Cambridge, MA 02142
Tel: 617-252-7500
Fax: 617-252-7600

Genzyme is one of the world’s foremost biotechnology companies. Founded in 1981, Genzyme has grown from a small start-up in Boston to a diversified enterprise with over 10,000 employees in locations spanning the globe. Genzyme’s passion, first and foremost, is to patients. Genzyme has translated this passion into products and services that provide significant positive impact on the lives of people with serious diseases, and that meet major unmet medical needs. Genzyme’s broad area of focus includes oncology, lysosomal storage disorders, renal disease, orthopaedics, transplant, immune diseases, and genetic disorders.

Genzyme is also one of the largest providers of diagnostic testing services in the world and a major supplier of diagnostic products. The company is playing an important role in the movement toward personalized medicine by developing tests that can help physicians identify how patients are likely to respond to targeted therapies.

In oncology, Genzyme’s product development expertise, robust research program, and strong global infrastructure provide a solid base for developing and commercializing novel treatments for cancer patients. Genzyme currently has several promising oncology therapies in clinical trials, including treatments for chronic lymphocytic leukemia and pediatric acute lymphocytic leukemia. Among its current oncology products are Campath® (alemtuzumab) and Clolar® (clofarabine). Additional information for Campath may be obtained at www.campath.com and for Clolar at www.clolar.com. (Campath® and Clolar® are registered trademarks of Genzyme Corporation.)

Genzyme’s ongoing discovery utilizes a broad range of target identification, target validation and drug development technologies, in active collaboration with select companies and academic institutions. Genzyme is striving to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments.

An innovative biotechnology company with a diverse portfolio of medical products, a deep scientific base with a truly global approach; a strong commitment to patients and community with a united sense of responsibility and shared values; a passion to solve problems that have not been solved; a drive to provide hope where there was none before—this is Genzyme.

back to top

Wyeth Pharmaceuticals
Wyeth
5 Giralda Farms
Madison, NJ 07940

Wyeth has a long history of pioneering developments in pharmaceuticals and biotechnology, with leading products in the areas of women’s health care, neuroscience, musculoskeletal disorders, cardiovascular therapy, vaccines and infectious disease, hemophilia, immunology and oncology. Wyeth also is a leader in the development of nutritionals.

Wyeth's work in immunology focuses on producing novel immunosuppressants for organ transplantation. Its efforts in oncology include chemotherapy agents for acute myeloid leukemia and a platelet growth promoter to help patients after chemotherapy. Wyeth currently has several promising oncology therapies in clinical trials, including treatments for renal cell carcinoma, breast cancer, and mantle cell lymphoma. Among its current oncology products are Mylotarg® (gemtuzumab ozogamicin for injection), Neumega® (oprelvekin); and Torisel™ (temsirolimus) injection.

ACCC's Emerging Companies Council is designed to provide companies with access to up-to-the-minute news and insight into cancer care issues not available through any other professional association.

For many years, Wyeth Pharmaceuticals has been committed to helping patients in need receive their medications. Through the Wyeth Patient Assistance Program, the Wyeth Pharmaceutical Assistance Foundation strives to ensure that eligible patients receive medications at no cost and in a timely manner. The following information answers common questions about our program and will assist with the application process.

To enroll a patient in the program, please complete the following steps:

• Obtain an application and privacy authorization form (see below).
• Complete the application in its entirety with the patient; please do not leave any section blank.
• Write a prescription for up to a 3-month supply and specify up to 3 refills, if appropriate. (Please note that Protonix® is limited to a 60-day supply.)
• Obtain the patient's signature on the privacy authorization form allowing specified disclosure of health information to the Wyeth Pharmaceutical Assistance Foundation and retain in patient's file.
• Mail the application form and prescription to the address indicated on the application.

The health care provider will determine whether the medication should be mailed to the patient's home or to the provider's office.

To receive general information, additional applications, and a list of products covered by the program via fax, call (800) 568-9938.

For more information, click here.

back to top